The new test will be designed to enable early treatment before reactivation of the TB disease, as a follow up to those who test positive for latent TB.
The company is believed to strengthen its infectious disease portfolio with development of DNA-/RNA-based test that complements QuantiFERON-TB Gold test for latent TB.
The new molecular reflex assay, which is likely to be a PCR-based test targeting multiple biomarkers, will be designed to run on the QIAsymphony modular automation platform.
The test will use whole blood transcription profiling, a new diagnostic technology developed at the Max Planck Institute’s Department of Immunology
The financial terms of the agreement have not been disclosed.